[1]梁灿灿,庞 澜,柯 月,等.非酒精性脂肪性肝病病人肠道微生态系统变化及其对机体炎症反应的影响机制[J].肠外与肠内营养杂志,2020,(06):335-339.[doi:10.16151/j.1007-810x.2020.06.004]
　LIANG Can-can,PANG Lan,KE Yue,et al.Effects of the change of intestinal microecosystem on inflammatory reaction in patients with non-alcoholic fatty liver disease and its mechanism[J].PARENTERAL & ENTERAL NUTRITION,2020,(06):335-339.[doi:10.16151/j.1007-810x.2020.06.004]
点击复制

非酒精性脂肪性肝病病人肠道微生态系统变化及其对机体炎症反应的影响机制
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2020年06期
页码:
335-339
栏目:
论著
出版日期:
2020-11-10

文章信息/Info

Title:
Effects of the change of intestinal microecosystem on inflammatory reaction in patients with non-alcoholic fatty liver disease and its mechanism
作者:
梁灿灿; 庞 澜; 柯 月; 丁 荣; 王 玥; 纪文静; 丁永年
新疆医科大学第二附属医院消化内科，新疆乌鲁木齐830028
Author(s):
LIANG Can-can;  PANG Lan;  KE Yue;  DING Rong;  WANG Yue;  JI Wen-jing;  DING Yong-nian
Department of Gastroenterology, the Second Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region,Wulumuqi 830028, Xinjiang, China
关键词:
非酒精性脂肪性肝病 ; 肠道微生态系统 ; 炎症反应 ; Toll样受体-4
Keywords:
Nonalcoholic fatty liver disease;  Intestinal microecosystem;  Inflammatory response;  Toll-like receptor-4
分类号:
R575
DOI:
10.16151/j.1007-810x.2020.06.004
文献标志码:
A
摘要:
目的：探讨非酒精性脂肪性肝病（NAFLD）病人的肠道微生态系统变化对机体炎症反应的影响机制。 方法：选择2018年07月至2019年07月入新疆医科大学第二附属医院首次确诊60例NAFLD病人作为观察组和60例健康体检者作为对照组。采用肠道微生物多样性分析技术检测观察组治疗前后和对照组的肠道菌群种类和数量，ELISA法检测炎症因子IL-6和TGF-β水平，Western blot法检测Toll样受体（TLR）-4和NF-κB（p65）蛋白水平。 结果：与治疗前比较，观察组治疗后BMI、LDL-C与总胆红素（CHO）显著降低（P < 0.05）。治疗前与对照组比较，观察组肠道菌群以大肠埃希菌、金黄色葡萄球菌、肠球菌为主的致病菌显著增加，而以乳酸杆菌、罗氏菌为主的益生菌显著减少（P < 0.05）。观察组治疗后与治疗前比较，致病菌数量减少，益生菌增加（P < 0.05）。治疗前与对照组比较，观察组血清IL-6、TGF-β、TLR-4和NF-κB（p65）蛋白水平明显升高（P < 0.05）。观察组治疗后与治疗前比较，血清IL-6、TGF-β、TLR-4和NF-κB（p65）蛋白水平显著降低（P < 0.05）。 结论：NAFLD病人肠道微生态系统出现致病菌增多，益生菌减少，并导致机体炎症相关因子表达的升高，可能是NAFLD发生和病情进展的重要机制之一。
Abstract:
Objective: To analyze the effect of the change of intestinal microecosystem on inflammatory reaction in patients with non-alcoholic fatty liver disease (NAFLD) and to explore its mechanism. Methods: A total of 60 patients diagnosed to NAFLD were enrolled into observation group from July 2018 to July 2019. And the 60 healthy examinees were enrolled into in control group. The kinds and quantities of intestinal flora of two groups were detected by intestinal microbial diversity analysis at pre- and post-therapy, respectively. The inflammatory factors levels of IL-6 and TGF-β were detected by ELISA. And the protein levels of Toll-like receptor (TLR)-4 and NF-κB (p65) were detected by Western blot. Results: The levels of BMI, LDL-C and CHO of observation group at post-therapy were obviously lower than at pre-therapy (P < 0.05). The pathogenic bacteria of Escherichia coli, Staphylococcus aureus and Enterococcus of observation group at pre-therapy were higher than control group (P < 0.05), but the probiotics of Lactobacillus and Rochella of observation group at pre-therapy were lower than control group (P < 0.05). Compared to pre-therapy, the quantities of pathogenic bacteria of observation group at post-therapy were obviously lower and the probiotics were higher (P < 0.05). The serum levels of IL-6、TGF-β、TLR-4 and NF-κB (p65) of observation group at pre-therapy were higher than control group (P < 0.05). Compared to pre-therapy, the serum levels of IL-6、TGF- β、TLR-4 and NF- κB (p65) of observation group at post-therapy were obviously lower (P < 0.05). Conclusion: The quantities of pathogenic bacteria of intestinal microecosystem in patients with NAFLD are increasing, but the probiotics are decreasing, which can up-regulate the inflammatory factor levels. It may be one of important mechanisms to the occurrence and progression of NAFLD.

参考文献/References:


[1] Lacono A, Raso GM, Canani RB, et a1. Probiotics as an emerging therapeutic strategy to treat NAFID: focus on molecular and biochemical mechanisms. J Nutr Biochem, 2016, 22(8): 699-711.
[2] 邓冠华, 查龙应, 张国霞, 等. 高通量16S rRNA标签测序法比较人与不同动物肠道微生物组多样性 . 生态科学, 2014, 33(5):851-857.
[3] Tyrovolas S, Panagiotakos DB, Georgousopoulou EN, et al. The anti-inflammatory potential of diet and nonalcoholic fatty liver disease: the ATTICA study. Therap Adv Gastroenterol, 2019, 12(6):165-166.
[4] Y?lmaz Y, Kani HT, Demirta? C?, et al. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turk J Gastroenterol, 2019, 30(10):892-898.
[5] 张 敏,陈 璐,瞿美娣, 等.2型糖尿病病人合并非酒精性脂肪性肝病的危险因素分析.肠外与肠内营养,2019,26(5):271-275.
[6] 罗安斐, 张名贤. 双歧杆菌三联活菌散联合复方甘草酸苷片治疗儿童非酒精性脂肪性肝病的临床研究 . 现代药物与临床,2018, 33(10): 2625-2628.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病防治指南（2018 更新版）. 临床肝胆病杂志, 2018, 34(5): 947-955.
[8] 王 为, 徐爱蕾, 周国华, 等. 非酒精性脂肪性肝病患者小肠细菌过度生长的情况. 临床消化病杂志, 2015, 27(2):67-69.
[9] 邢现峰. 非酒精性脂肪性肝病细菌感染的细菌类型及耐药性分析. 肝脏, 2016, 21(1):52-54.
[10] 张 宇, 王威巍, 左国华, 等. 粪便细菌移植对非酒精性脂肪性肝病大鼠肝功能和脂代谢紊乱的影响 . 第三军医大学学报,2019, 41(13):1200-1205.
[11] 池肇春. 肠道细菌与非酒精性脂肪性肝病研究进展与现状. 中西医结合肝病杂志, 2019, 29(2):97-102.
[12] 陈 洁, 陈佳良, 肖琨珉, 等. 炎症因子与非酒精性脂肪性肝病关系研究进展. 医学综述, 2019, 17(15):2949-2954.
[13] 王报贵, 许海波, 杜 文, 等. 基于肠道菌群探讨泡菜中乳酸菌防治非酒精性脂肪肝的研究 . 食品工业科技, 2020,41(17):320-326.
[14] 王晓晓, 饶慧瑛, 刘 峰. 非酒精性脂肪性肝病发病机制研究进展——聚焦“巨噬细胞及其分子机制”. 医学综述, 2019, 18(15):2929-2934.
[15] Hwang YC, Ahn HY, Park CY. Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study. Obesity, 2019, 27(8): 1360- 1366.
[16] 夏 凡, 周本杰. 肠-肝轴功能紊乱在非酒精性脂肪肝病发病机制中的作用及相关治疗策略 . 世界华人消化杂志, 2018, 26(24): 1439-1447.
[17] Cheraghpour M, Imani H, Ommi S, et al. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res, 2019, 33(8):2118-2125.
[18] Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol, 2019, 12(6):175-177.
[19] 杨 波, 铁宝霞, 蔡小玲, 等. 肠道微生态研究方法及应用研究进展. 广西医学, 2018, 40(10):1219-1221.

相似文献/References:

[1]张 敏,陈 璐,瞿美娣,等.2型糖尿病病人合并非酒精性脂肪性肝病的危险因素分析[J].肠外与肠内营养杂志,2019,(05):271.[doi:DOI : 10.16151/j.1007-810x.2019.05.004]
　ZHANG Min,CHEN Lu,Q? Mei-di,et al.Analysis of the risk factors for NAFLD in patients with T2DM[J].PARENTERAL & ENTERAL NUTRITION,2019,(06):271.[doi:DOI : 10.16151/j.1007-810x.2019.05.004]

备注/Memo

备注/Memo:
基金项目 ：新疆维吾尔自治区科技厅科研创新项目（XJC201361） 作者简介 ：梁灿灿，主治医师，医学硕士，从事非酒精性脂肪性肝病的研究。E-mail:1164124600@qq.com 通讯作者 ：丁永年，E-mail：313269733@qq.com
更新日期/Last Update: 1900-01-01